{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "33226291",
   "metadata": {},
   "source": [
    "title 전처리 및 자카르트 유사도, recall"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "5026ba89",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "매칭된 title 개수: 29\n",
      "                                            title_t0  \\\n",
      "0  conditionally reprogrammed colorectal cancer c...   \n",
      "1  activation of the mtor pathway by oxaliplatin ...   \n",
      "2  evaluation of the efficacy of dasatinib a src ...   \n",
      "3  bgb 283 a novel raf kinase and egfr inhibitor ...   \n",
      "4  synergistic anti tumor effect of mtor inhibito...   \n",
      "5  integrative in vivo drug testing using gene ex...   \n",
      "6  mtor inhibition and t dm1 in her2 positive bre...   \n",
      "7  dual fatty acid synthase and her2 signaling bl...   \n",
      "8  dz 2384 has a superior preclinical profile to ...   \n",
      "9  jak2 regulates paclitaxel resistance in triple...   \n",
      "\n",
      "                                            title_t1  similarity  \\\n",
      "0  conditionally reprogrammed colorectal cancer c...    1.000000   \n",
      "1  activation of the mtor pathway by oxaliplatin ...    1.000000   \n",
      "2  evaluation of the efficacy of dasatinib a src ...    0.842105   \n",
      "3  bgb 283 a novel raf kinase and egfr inhibitor ...    0.842105   \n",
      "4  synergistic anti tumor e ect of mtor inhibitor...    0.800000   \n",
      "5  integrative in vivo drug testing using gene ex...    1.000000   \n",
      "6  mtor inhibition and trastuzumab emtansine t dm...    0.833333   \n",
      "7  dual fatty acid synthase and her2 signaling bl...    1.000000   \n",
      "8  dz 2384 has a superior preclinical profile to ...    1.000000   \n",
      "9  jak2 regulates paclitaxel resistance in triple...    1.000000   \n",
      "\n",
      "                                             drug_t0  \\\n",
      "0      cetuximab; palbociclib; sorafenib; trametinib   \n",
      "1                            everolimus; oxaliplatin   \n",
      "2                                          dasatinib   \n",
      "3        bgb-283 (lifirafenib); cetuximab; erlotinib   \n",
      "4                   azd2014; irinotecan; oxaliplatin   \n",
      "5  bevacizumab; docetaxel; everolimus; neratinib;...   \n",
      "6                                  everolimus; t-md1   \n",
      "7                                 egcg; temsirolimus   \n",
      "8                                dz-2384; paclitaxel   \n",
      "9                                         paclitaxel   \n",
      "\n",
      "                                             drug_t1  drug_overlap  \n",
      "0                                                  -         False  \n",
      "1                             OXALIPLATIN;EVEROLIMUS          True  \n",
      "2                                          DASATINIB          True  \n",
      "3                   LIFIRAFENIB;DABRAFENIB;CETUXIMAB          True  \n",
      "4                             IRINOTECAN;VISTUSERTIB          True  \n",
      "5  SORAFENIB;EVEROLIMUS;DOCETAXEL;BEVACIZUMAB;PX-...          True  \n",
      "6                   EVEROLIMUS;TRASTUZUMAB EMTANSINE          True  \n",
      "7                   TRASTUZUMAB;LAPATINIB;PERTUZUMAB         False  \n",
      "8  DOCETAXEL;PACLITAXEL;DZ-2384;METHOTREXATE;CHLO...          True  \n",
      "9                             PACLITAXEL;GEMCITABINE          True  \n",
      "Drug Recall (유사 title + drug 포함 기준): 0.1667\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import re\n",
    "\n",
    "# CSV 불러오기\n",
    "t0 = pd.read_csv(\"t0.csv\", encoding='cp949')\n",
    "t1 = pd.read_csv(\"t1.csv\", encoding='utf-8')\n",
    "\n",
    "# 1️⃣ title 전처리\n",
    "def preprocess_title(title):\n",
    "    if pd.isna(title):\n",
    "        return \"\"\n",
    "    title = title.lower()  # 소문자 통일\n",
    "    title = re.sub(r\"[\\-;,/():]\", \" \", title)  # 특수문자 제거\n",
    "    title = re.sub(r\"\\s+\", \" \", title)  # 공백 통일\n",
    "    title = title.strip()\n",
    "    return title\n",
    "\n",
    "t0[\"title\"] = t0[\"title\"].apply(preprocess_title)\n",
    "t1[\"title\"] = t1[\"title\"].apply(preprocess_title)\n",
    "\n",
    "# 2️⃣ Jaccard 유사도 함수\n",
    "def jaccard_similarity(str1, str2):\n",
    "    set1 = set(str1.split())\n",
    "    set2 = set(str2.split())\n",
    "    if not set1 or not set2:\n",
    "        return 0\n",
    "    return len(set1 & set2) / len(set1 | set2)\n",
    "\n",
    "threshold = 0.7  # 유사도 기준 (조정 가능)\n",
    "\n",
    "# 3️⃣ title 유사도 기반 매칭\n",
    "matches = []\n",
    "for i, row0 in t0.iterrows():\n",
    "    for j, row1 in t1.iterrows():\n",
    "        sim = jaccard_similarity(row0[\"title\"], row1[\"title\"])\n",
    "        if sim >= threshold:\n",
    "            matches.append({\n",
    "                \"idx_t0\": i,\n",
    "                \"idx_t1\": j,\n",
    "                \"title_t0\": row0[\"title\"],\n",
    "                \"title_t1\": row1[\"title\"],\n",
    "                \"similarity\": sim,\n",
    "                \"drug_t0\": row0[\"drug\"],\n",
    "                \"drug_t1\": row1[\"drug\"]\n",
    "            })\n",
    "\n",
    "matched_df = pd.DataFrame(matches)\n",
    "\n",
    "# 4️⃣ drug 전처리 및 공통 여부 확인\n",
    "def normalize_drug(drug_str):\n",
    "    if pd.isna(drug_str):\n",
    "        return []\n",
    "    return [d.strip().lower() for d in drug_str.split(\";\")]\n",
    "\n",
    "matched_df[\"drug_t0_list\"] = matched_df[\"drug_t0\"].apply(normalize_drug)\n",
    "matched_df[\"drug_t1_list\"] = matched_df[\"drug_t1\"].apply(normalize_drug)\n",
    "matched_df[\"drug_overlap\"] = matched_df.apply(\n",
    "    lambda x: len(set(x[\"drug_t0_list\"]) & set(x[\"drug_t1_list\"])) > 0, axis=1\n",
    ")\n",
    "\n",
    "# 5️⃣ 결과 확인\n",
    "print(f\"매칭된 title 개수: {matched_df.shape[0]}\")\n",
    "print(matched_df[[\"title_t0\", \"title_t1\", \"similarity\", \"drug_t0\", \"drug_t1\", \"drug_overlap\"]].head(10))\n",
    "\n",
    "# 6️⃣ drug 재현율 계산 (t0 기준)\n",
    "recall = matched_df[\"drug_overlap\"].sum() / t0[\"drug\"].nunique()\n",
    "print(f\"Drug Recall (유사 title + drug 포함 기준): {recall:.4f}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "43466326",
   "metadata": {},
   "outputs": [],
   "source": [
    "# 약물 소문자로 변환 후 ; 기준으로 리스트화\n",
    "def normalize_drug(drug_str):\n",
    "    return [d.strip().lower() for d in drug_str.split(\";\")]\n",
    "\n",
    "matched_df[\"drug_t0_list\"] = matched_df[\"drug_t0\"].apply(normalize_drug)\n",
    "matched_df[\"drug_t1_list\"] = matched_df[\"drug_t1\"].apply(normalize_drug)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "ad0369b4",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Drug Recall (유사 title + drug 포함 기준): 0.1667\n"
     ]
    }
   ],
   "source": [
    "# drug overlap 여부 확인\n",
    "matched_df[\"drug_overlap\"] = matched_df.apply(\n",
    "    lambda x: len(set(x[\"drug_t0_list\"]) & set(x[\"drug_t1_list\"])) > 0, axis=1\n",
    ")\n",
    "\n",
    "# t0 기준 재현율\n",
    "recall = matched_df[\"drug_overlap\"].sum() / t0[\"drug\"].nunique()\n",
    "print(f\"Drug Recall (유사 title + drug 포함 기준): {recall:.4f}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "d65e5464",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "=== t0 전처리된 title 예시 ===\n",
      "0    conditionally reprogrammed colorectal cancer cells combined with mouse avatars identify synergy between egfr and mek or cdk4 6 inhibitors\n",
      "1                  combining mek and src inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo\n",
      "2                                           sensitivity of kras mutant colorectal cancers to combination therapy that cotargets mek and cdk4 6\n",
      "3                                                                targeting ras mutant colorectal cancer with dual inhibition of mek and cdk4 6\n",
      "4                                                mcl 1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer\n",
      "Name: title, dtype: object\n",
      "\n",
      "=== t1 전처리된 title 예시 ===\n",
      "0                                                      cdk4 6 inhibitors impede chemoresistance and inhibit tumor growth of small cell lung cancer\n",
      "1        conditionally reprogrammed colorectal cancer cells combined with mouse avatars identify synergy between egfr and mek or cdk4 6 inhibitors\n",
      "2    krt 232 and navitoclax enhance trametinib’s anti cancer activity in non small cell lung cancer patient derived xenografts with kras mutations\n",
      "3                              bgb 283 a novel raf kinase and egfr inhibitor displays potent antitumor activity in braf mutated colorectal cancers\n",
      "4                         acquired resistance to trastuzumab pertuzumab or to t dm1 in vivo can be overcome by her2 kinase inhibition with tas0728\n",
      "Name: title, dtype: object\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import re\n",
    "\n",
    "# CSV 불러오기\n",
    "# t0 = pd.read_csv(\"t0.csv\")\n",
    "# t1 = pd.read_csv(\"t1.csv\")\n",
    "\n",
    "# 1️⃣ title 전처리 함수\n",
    "def preprocess_title(title):\n",
    "    if pd.isna(title):\n",
    "        return \"\"\n",
    "    title = title.lower()  # 소문자 통일\n",
    "    title = re.sub(r\"[\\-;,/():]\", \" \", title)  # 특수문자 제거\n",
    "    title = re.sub(r\"\\s+\", \" \", title)  # 공백 통일\n",
    "    title = title.strip()\n",
    "    return title\n",
    "\n",
    "# 2️⃣ t0, t1의 title 컬럼 전처리\n",
    "t0[\"title\"] = t0[\"title\"].apply(preprocess_title)\n",
    "t1[\"title\"] = t1[\"title\"].apply(preprocess_title)\n",
    "\n",
    "# 3️⃣ 전처리 확인 (상위 5개)\n",
    "print(\"=== t0 전처리된 title 예시 ===\")\n",
    "print(t0[\"title\"].head())\n",
    "print(\"\\n=== t1 전처리된 title 예시 ===\")\n",
    "print(t1[\"title\"].head())\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "b7324762",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "매칭된 title 개수: 29\n",
      "  title_t0                                                                                                                                                                                \\\n",
      "0                                              conditionally reprogrammed colorectal cancer cells combined with mouse avatars identify synergy between egfr and mek or cdk4 6 inhibitors   \n",
      "1                                                                                   activation of the mtor pathway by oxaliplatin in the treatment of colorectal cancer liver metastasis   \n",
      "2                                                                    evaluation of the efficacy of dasatinib a src abl inhibitor in colorectal cancer cell lines and explant mouse model   \n",
      "3                                                                    bgb 283 a novel raf kinase and egfr inhibitor displays potent antitumor activity in?braf mutated colorectal cancers   \n",
      "4                                                                                                 synergistic anti tumor effect of mtor inhibitors with irinotecan on colon cancer cells   \n",
      "5  integrative in vivo drug testing using gene expression signature and patient derived xenografts from treatment refractory her2 positive and triple negative subtypes of breast cancer   \n",
      "6                                                                                                                               mtor inhibition and t dm1 in her2 positive breast cancer   \n",
      "7                                         dual fatty acid synthase and her2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti her2 drugs   \n",
      "8                             dz 2384 has a superior preclinical profile to taxanes for the treatment of triple negative breast cancer and is synergistic with anti ctla 4 immunotherapy   \n",
      "9                                                                                                                 jak2 regulates paclitaxel resistance in triple negative breast cancers   \n",
      "\n",
      "  title_t1                                                                                                                                                                                \\\n",
      "0                                              conditionally reprogrammed colorectal cancer cells combined with mouse avatars identify synergy between egfr and mek or cdk4 6 inhibitors   \n",
      "1                                                                                   activation of the mtor pathway by oxaliplatin in the treatment of colorectal cancer liver metastasis   \n",
      "2                                                                     evaluation of the efficacy of dasatinib a src abl inhibitor in colorectal cancer cell lines and explant mousemodel   \n",
      "3                                                                    bgb 283 a novel raf kinase and egfr inhibitor displays potent antitumor activity in braf mutated colorectal cancers   \n",
      "4                                                                                                  synergistic anti tumor e ect of mtor inhibitors with irinotecan on colon cancer cells   \n",
      "5  integrative in vivo drug testing using gene expression signature and patient derived xenografts from treatment refractory her2 positive and triple negative subtypes of breast cancer   \n",
      "6                                                                                                         mtor inhibition and trastuzumab emtansine t dm1 in her2 positive breast cancer   \n",
      "7                                         dual fatty acid synthase and her2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti her2 drugs   \n",
      "8                             dz 2384 has a superior preclinical profile to taxanes for the treatment of triple negative breast cancer and is synergistic with anti ctla 4 immunotherapy   \n",
      "9                                                                                                                 jak2 regulates paclitaxel resistance in triple negative breast cancers   \n",
      "\n",
      "   similarity  \\\n",
      "0  1.000000     \n",
      "1  1.000000     \n",
      "2  0.842105     \n",
      "3  0.842105     \n",
      "4  0.800000     \n",
      "5  1.000000     \n",
      "6  0.833333     \n",
      "7  1.000000     \n",
      "8  1.000000     \n",
      "9  1.000000     \n",
      "\n",
      "  drug_t0                                                            \\\n",
      "0                     cetuximab; palbociclib; sorafenib; trametinib   \n",
      "1                                           everolimus; oxaliplatin   \n",
      "2                                                         dasatinib   \n",
      "3                       bgb-283 (lifirafenib); cetuximab; erlotinib   \n",
      "4                                  azd2014; irinotecan; oxaliplatin   \n",
      "5  bevacizumab; docetaxel; everolimus; neratinib; px-478; sorafenib   \n",
      "6                                                 everolimus; t-md1   \n",
      "7                                                egcg; temsirolimus   \n",
      "8                                               dz-2384; paclitaxel   \n",
      "9                                                        paclitaxel   \n",
      "\n",
      "  drug_t1                                                                                                                                             \\\n",
      "0                                                                                                                                                  -   \n",
      "1                                                                                                                             OXALIPLATIN;EVEROLIMUS   \n",
      "2                                                                                                                                          DASATINIB   \n",
      "3                                                                                                                   LIFIRAFENIB;DABRAFENIB;CETUXIMAB   \n",
      "4                                                                                                                             IRINOTECAN;VISTUSERTIB   \n",
      "5                                                                                        SORAFENIB;EVEROLIMUS;DOCETAXEL;BEVACIZUMAB;PX-478;NERATINIB   \n",
      "6                                                                                                                   EVEROLIMUS;TRASTUZUMAB EMTANSINE   \n",
      "7                                                                                                                   TRASTUZUMAB;LAPATINIB;PERTUZUMAB   \n",
      "8  DOCETAXEL;PACLITAXEL;DZ-2384;METHOTREXATE;CHLORAMBUCIL;anthracyclines;RITONAVIR;ELACRIDAR;SORAFENIB;FULVESTRANT;SUNITINIB;NIVOLUMAB;PEMBROLIZUMAB   \n",
      "9                                                                                                                             PACLITAXEL;GEMCITABINE   \n",
      "\n",
      "   drug_overlap  \n",
      "0  False         \n",
      "1   True         \n",
      "2   True         \n",
      "3   True         \n",
      "4   True         \n",
      "5   True         \n",
      "6   True         \n",
      "7  False         \n",
      "8   True         \n",
      "9   True         \n",
      "Drug Recall (유사 title + drug 포함 기준): 0.1667\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import re\n",
    "\n",
    "# CSV 불러오기\n",
    "# t0 = pd.read_csv(\"t0.csv\")\n",
    "# t1 = pd.read_csv(\"t1.csv\")\n",
    "\n",
    "# 1️⃣ title 전처리\n",
    "def preprocess_title(title):\n",
    "    if pd.isna(title):\n",
    "        return \"\"\n",
    "    title = title.lower()  # 소문자 통일\n",
    "    title = re.sub(r\"[\\-;,/():]\", \" \", title)  # 특수문자 제거\n",
    "    title = re.sub(r\"\\s+\", \" \", title)  # 공백 통일\n",
    "    title = title.strip()\n",
    "    return title\n",
    "\n",
    "t0[\"title\"] = t0[\"title\"].apply(preprocess_title)\n",
    "t1[\"title\"] = t1[\"title\"].apply(preprocess_title)\n",
    "\n",
    "# 2️⃣ Jaccard 유사도 함수\n",
    "def jaccard_similarity(str1, str2):\n",
    "    set1 = set(str1.split())\n",
    "    set2 = set(str2.split())\n",
    "    if not set1 or not set2:\n",
    "        return 0\n",
    "    return len(set1 & set2) / len(set1 | set2)\n",
    "\n",
    "threshold = 0.7  # 유사도 기준 (조정 가능)\n",
    "\n",
    "# 3️⃣ title 유사도 기반 매칭\n",
    "matches = []\n",
    "for i, row0 in t0.iterrows():\n",
    "    for j, row1 in t1.iterrows():\n",
    "        sim = jaccard_similarity(row0[\"title\"], row1[\"title\"])\n",
    "        if sim >= threshold:\n",
    "            matches.append({\n",
    "                \"idx_t0\": i,\n",
    "                \"idx_t1\": j,\n",
    "                \"title_t0\": row0[\"title\"],\n",
    "                \"title_t1\": row1[\"title\"],\n",
    "                \"similarity\": sim,\n",
    "                \"drug_t0\": row0[\"drug\"],\n",
    "                \"drug_t1\": row1[\"drug\"]\n",
    "            })\n",
    "\n",
    "matched_df = pd.DataFrame(matches)\n",
    "\n",
    "# 4️⃣ drug 전처리 및 공통 여부 확인\n",
    "def normalize_drug(drug_str):\n",
    "    if pd.isna(drug_str):\n",
    "        return []\n",
    "    return [d.strip().lower() for d in drug_str.split(\";\")]\n",
    "\n",
    "matched_df[\"drug_t0_list\"] = matched_df[\"drug_t0\"].apply(normalize_drug)\n",
    "matched_df[\"drug_t1_list\"] = matched_df[\"drug_t1\"].apply(normalize_drug)\n",
    "matched_df[\"drug_overlap\"] = matched_df.apply(\n",
    "    lambda x: len(set(x[\"drug_t0_list\"]) & set(x[\"drug_t1_list\"])) > 0, axis=1\n",
    ")\n",
    "\n",
    "# 5️⃣ 결과 확인\n",
    "print(f\"매칭된 title 개수: {matched_df.shape[0]}\")\n",
    "print(matched_df[[\"title_t0\", \"title_t1\", \"similarity\", \"drug_t0\", \"drug_t1\", \"drug_overlap\"]].head(10))\n",
    "\n",
    "# 6️⃣ drug 재현율 계산 (t0 기준)\n",
    "recall = matched_df[\"drug_overlap\"].sum() / t0[\"drug\"].nunique()\n",
    "print(f\"Drug Recall (유사 title + drug 포함 기준): {recall:.4f}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "aa7dcc51",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "=== t0 전처리된 drug ===\n",
      "  drug                                            \\\n",
      "0  cetuximab; palbociclib; sorafenib; trametinib   \n",
      "1                          dasatinib; trametinib   \n",
      "2                        palbociclib; trametinib   \n",
      "3                        palbociclib; trametinib   \n",
      "4                            regorafenib; s63845   \n",
      "\n",
      "  drug_list                                         \n",
      "0  [cetuximab, palbociclib, sorafenib, trametinib]  \n",
      "1                          [dasatinib, trametinib]  \n",
      "2                        [palbociclib, trametinib]  \n",
      "3                        [palbociclib, trametinib]  \n",
      "4                            [regorafenib, s63845]  \n",
      "\n",
      "=== t1 전처리된 drug ===\n",
      "  drug                                                             \\\n",
      "0                                                   PALLADIUM;LEE   \n",
      "1                                                               -   \n",
      "2                               TRAMETINIB;NAVITOCLAX;NAVTEMADLIN   \n",
      "3                                LIFIRAFENIB;DABRAFENIB;CETUXIMAB   \n",
      "4  LAPATINIB;TRASTUZUMAB;PERTUZUMAB;TRASTUZUMAB EMTANSINE;TAS0728   \n",
      "\n",
      "  drug_list                                                              \n",
      "0                                                      [palladium, lee]  \n",
      "1                                                                   [-]  \n",
      "2                                 [trametinib, navitoclax, navtemadlin]  \n",
      "3                                  [lifirafenib, dabrafenib, cetuximab]  \n",
      "4  [lapatinib, trastuzumab, pertuzumab, trastuzumab emtansine, tas0728]  \n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "\n",
    "# 예시: t0, t1 이미 불러온 상태\n",
    "# t0['drug'], t1['drug'] 컬럼 존재\n",
    "\n",
    "# 1️⃣ drug 전처리 함수\n",
    "def preprocess_drug(drug_str):\n",
    "    if pd.isna(drug_str):\n",
    "        return []\n",
    "    # ; 구분, 소문자, 공백 제거\n",
    "    return [d.strip().lower() for d in drug_str.split(\";\") if d.strip()]\n",
    "\n",
    "# 2️⃣ t0, t1 drug 컬럼 전처리\n",
    "t0[\"drug_list\"] = t0[\"drug\"].apply(preprocess_drug)\n",
    "t1[\"drug_list\"] = t1[\"drug\"].apply(preprocess_drug)\n",
    "\n",
    "# 3️⃣ 전처리 확인 (상위 5개)\n",
    "print(\"=== t0 전처리된 drug ===\")\n",
    "print(t0[[\"drug\", \"drug_list\"]].head())\n",
    "print(\"\\n=== t1 전처리된 drug ===\")\n",
    "print(t1[[\"drug\", \"drug_list\"]].head())\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "461fd88b",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "====================================\n",
      "Title T0: conditionally reprogrammed colorectal cancer cells combined with mouse avatars identify synergy between egfr and mek or cdk4 6 inhibitors\n",
      "Title T1: conditionally reprogrammed colorectal cancer cells combined with mouse avatars identify synergy between egfr and mek or cdk4 6 inhibitors\n",
      "Drug T0: ['CETUXIMAB', 'PALBOCICLIB', 'SORAFENIB', 'TRAMETINIB']\n",
      "Drug T1: ['-']\n",
      "Overlap: False\n",
      "====================================\n",
      "Title T0: activation of the mtor pathway by oxaliplatin in the treatment of colorectal cancer liver metastasis\n",
      "Title T1: activation of the mtor pathway by oxaliplatin in the treatment of colorectal cancer liver metastasis\n",
      "Drug T0: ['EVEROLIMUS', 'OXALIPLATIN']\n",
      "Drug T1: ['OXALIPLATIN', 'EVEROLIMUS']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: evaluation of the efficacy of dasatinib a src abl inhibitor in colorectal cancer cell lines and explant mouse model\n",
      "Title T1: evaluation of the efficacy of dasatinib a src abl inhibitor in colorectal cancer cell lines and explant mousemodel\n",
      "Drug T0: ['DASATINIB']\n",
      "Drug T1: ['DASATINIB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: lowdose trametinib and bclxl antagonist have a specific antitumor effect in krasmutated colorectal cancer cells\n",
      "Title T1: lowdose trametinib and bclxl antagonist have a specific antitumor effect in krasmutated colorectal cancer cells\n",
      "Drug T0: ['abt263', 'TRAMETINIB']\n",
      "Drug T1: ['TRAMETINIB', 'ABT263']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: bgb 283 a novel raf kinase and egfr inhibitor displays potent antitumor activity inbraf mutated colorectal cancers\n",
      "Title T1: bgb 283 a novel raf kinase and egfr inhibitor displays potent antitumor activity in braf mutated colorectal cancers\n",
      "Drug T0: ['bgb-283 (lifirafenib)', 'CETUXIMAB', 'ERLOTINIB']\n",
      "Drug T1: ['LIFIRAFENIB', 'DABRAFENIB', 'CETUXIMAB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: synergistic anti tumor effect of mtor inhibitors with irinotecan on colon cancer cells\n",
      "Title T1: synergistic anti tumor e ect of mtor inhibitors with irinotecan on colon cancer cells\n",
      "Drug T0: ['VISTUSERTIB', 'IRINOTECAN', 'OXALIPLATIN']\n",
      "Drug T1: ['IRINOTECAN', 'VISTUSERTIB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: integrative in vivo drug testing using gene expression signature and patient derived xenografts from treatment refractory her2 positive and triple negative subtypes of breast cancer\n",
      "Title T1: integrative in vivo drug testing using gene expression signature and patient derived xenografts from treatment refractory her2 positive and triple negative subtypes of breast cancer\n",
      "Drug T0: ['BEVACIZUMAB', 'DOCETAXEL', 'EVEROLIMUS', 'NERATINIB', 'PX-478', 'SORAFENIB']\n",
      "Drug T1: ['SORAFENIB', 'EVEROLIMUS', 'DOCETAXEL', 'BEVACIZUMAB', 'PX-478', 'NERATINIB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: dual fatty acid synthase and her2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti her2 drugs\n",
      "Title T1: dual fatty acid synthase and her2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti her2 drugs\n",
      "Drug T0: ['EPIGALLOCATECHIN GALLATE', 'TEMSIROLIMUS']\n",
      "Drug T1: ['TRASTUZUMAB', 'LAPATINIB', 'PERTUZUMAB']\n",
      "Overlap: False\n",
      "====================================\n",
      "Title T0: dz 2384 has a superior preclinical profile to taxanes for the treatment of triple negative breast cancer and is synergistic with anti ctla 4 immunotherapy\n",
      "Title T1: dz 2384 has a superior preclinical profile to taxanes for the treatment of triple negative breast cancer and is synergistic with anti ctla 4 immunotherapy\n",
      "Drug T0: ['dz-2384', 'PACLITAXEL']\n",
      "Drug T1: ['DOCETAXEL', 'PACLITAXEL', 'DZ-2384', 'METHOTREXATE', 'CHLORAMBUCIL', 'anthracyclines', 'RITONAVIR', 'ELACRIDAR', 'SORAFENIB', 'FULVESTRANT', 'SUNITINIB', 'NIVOLUMAB', 'PEMBROLIZUMAB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: jak2 regulates paclitaxel resistance in triple negative breast cancers\n",
      "Title T1: jak2 regulates paclitaxel resistance in triple negative breast cancers\n",
      "Drug T0: ['PACLITAXEL']\n",
      "Drug T1: ['PACLITAXEL', 'GEMCITABINE']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: wnt catenin inhibition disrupts carboplatin resistance in isogenic models of triple negative breast cancer\n",
      "Title T1: wnt catenin inhibition disrupts carboplatin resistance in isogenic models of triple negative breast cancer\n",
      "Drug T0: ['CARBOPLATIN', 'WNT-974']\n",
      "Drug T1: ['CARBOPLATIN', 'Wnt inhibitor', 'CHIR', 'DIMETHYL SULFOXIDE']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: acquired resistance to trastuzumab pertuzumab or to t dm1 in vivo can be overcome by her2 kinase inhibition with tas0728\n",
      "Title T1: acquired resistance to trastuzumab pertuzumab or to t dm1 in vivo can be overcome by her2 kinase inhibition with tas0728\n",
      "Drug T0: ['tas0728', 'TRASTUZUMAB', 'PERTUZUMAB']\n",
      "Drug T1: ['LAPATINIB', 'TRASTUZUMAB', 'PERTUZUMAB', 'TRASTUZUMAB EMTANSINE', 'TAS0728']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: the iron chelator deferasirox synergises with chemotherapy to treat triple negative breast cancers\n",
      "Title T1: the iron chelator deferasirox synergises with chemotherapy to treat triple negative breast cancers\n",
      "Drug T0: ['adriamycin (doxorubicin)', 'dfx', 'CYCLOPHOSPHAMIDE']\n",
      "Drug T1: ['DOXORUBICIN', 'CISPLATIN', 'CARBOPLATIN', 'CYCLOPHOSPHAMIDE', 'DEFERASIROX']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: identification of src family kinases as potential therapeutic targets for chemotherapy resistant triple negative breast cancer\n",
      "Title T1: identification of src family kinases as potential therapeutic targets for chemotherapy resistant triple negative breast cancer\n",
      "Drug T0: ['DASATINIB', 'PACLITAXEL']\n",
      "Drug T1: ['DASATINIB', 'PACLITAXEL']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: evaluation of combined chemotherapy and genomic driven targeted therapy in patient derived xenografts identifies new therapeutic approaches in squamous non small cell lung cancer patients\n",
      "Title T1: evaluation of combined chemotherapy and genomic driven targeted therapy in patient derived xenografts identifies new therapeutic approaches in squamous non small cell lung cancer patients\n",
      "Drug T0: ['CARBOPLATIN', 'CISPLATIN', 'ETOPOSIDE', 'GEMCITABINE', 'PACLITAXEL', 'PEMETREXED']\n",
      "Drug T1: ['SORAFENIB', 'GEMCITABINE', 'CISPLATIN', 'BEVACIZUMAB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: cdk4 6 inhibitors impede chemoresistance and inhibit tumor growth of small cell lung cancer\n",
      "Title T1: cdk4 6 inhibitors impede chemoresistance and inhibit tumor growth of small cell lung cancer\n",
      "Drug T0: ['CISPLATIN', 'ETOPOSIDE']\n",
      "Drug T1: ['PALLADIUM', 'LEE']\n",
      "Overlap: False\n",
      "====================================\n",
      "Title T0: cisplatin increases sensitivity to fgfr inhibition in patient derived xenograft models of lung squamous cell carcinoma\n",
      "Title T1: cisplatin increases sensitivity to fgfr inhibition in patient derived xenograft models of lung squamous cell carcinoma\n",
      "Drug T0: ['INFIGRATINIB', 'CISPLATIN']\n",
      "Drug T1: ['CISPLATIN', 'INFIGRATINIB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: sensitization of egfr wild type nonsmall cell lung cancer cells to egfr tyrosine kinase inhibitor erlotinib\n",
      "Title T1: sensitization of egfr wild type non small cell lung cancer cells to egfr tyrosine kinase inhibitor erlotinib\n",
      "Drug T0: ['CISPLATIN', 'ERLOTINIB']\n",
      "Drug T1: ['CISPLATIN', 'ERLOTINIB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: oral estrogen receptor protac vepdegestrant arv 471 is highly efficacious as monotherapy and in combination with cdk4 6 or pi3k mtor pathway inhibitors in preclinical erbreast cancer models\n",
      "Title T1: oral estrogen receptor protac vepdegestrant arv 471 is highly efficacious as monotherapy and in combination with cdk4 6 or pi3k mtor pathway inhibitors in preclinical er breast cancer models\n",
      "Drug T0: ['FULVESTRANT']\n",
      "Drug T1: ['FULVESTRANT', 'AZD-9496', 'VEPDEGESTRANT']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: her4 affects sensitivity to tamoxifen and abemaciclib in luminal breast cancer cells and restricts tumor growth in mcf 7 based humanized tumor mice\n",
      "Title T1: her4affects sensitivity to tamoxifen and abemaciclib in luminal breast cancer cells and restricts tumor growth in mcf 7 based humanized tumor mice\n",
      "Drug T0: ['ABEMACICLIB', 'TAMOXIFEN']\n",
      "Drug T1: ['RITUXIMAB', 'PEMBROLIZUMAB', 'NIVOLUMAB', 'FULVESTRANT', 'SUNITINIB']\n",
      "Overlap: False\n",
      "====================================\n",
      "Title T0: mediator kinase inhibitors suppress triple negative breast cancer growth and extend tumor suppression by mtor and akt inhibitors\n",
      "Title T1: mediator kinase inhibitors suppress triple negative breast cancer growth and extend tumor suppression by mtor and akt inhibitors\n",
      "Drug T0: ['CAPIVASERTIB', 'EVEROLIMUS']\n",
      "Drug T1: ['EVEROLIMUS', 'CDK8/19i']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: brca1 methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form rad51 foci and respond poorly to olaparib\n",
      "Title T1: brca1 methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form rad51 foci and respond poorly to olaparib\n",
      "Drug T0: ['CARBOPLATIN', 'OLAPARIB']\n",
      "Drug T1: ['OLAPARIB', '4-CHLOROBENZOPHENONE']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: rb expression confers sensitivity to cdk4 6 inhibitormediated radiosensitization across breast cancer subtypes\n",
      "Title T1: rb expression confers sensitivity to cdk4 6 inhibitormediated radiosensitization across breast cancer subtypes\n",
      "Drug T0: ['ABEMACICLIB', 'PALBOCICLIB']\n",
      "Drug T1: ['PALBOCICLIB', 'RIBOCICLIB', 'ABEMACICLIB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: comparative study on the efficacy and exposure of molecular target agents in nonsmall cell lung cancer pdx models with driver genetic alterations\n",
      "Title T1: comparative study on the efficacy and exposure of molecular target agents in non small cell lung cancer pdx models with driver genetic alterations\n",
      "Drug T0: ['AFATINIB', 'BRIGATINIB', 'CRIZOTINIB', 'ENTRECTINIB', 'GEFITINIB', 'LORLATINIB', 'OSIMERTINIB']\n",
      "Drug T1: ['GEFITINIB', 'OSIMERTINIB', 'AFATINIB', 'CRIZOTINIB', 'ENTRECTINIB', 'BRIGATINIB', 'LORLATINIB', 'POZIOTINIB', 'TRASTUZUMAB DERUXTECAN']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: the lifted veil of uncommon egfr mutation pl747p in non small cell lung cancer molecular feature and targeting sensitivity to tyrosine kinase inhibitors\n",
      "Title T1: the lifted veil of uncommon egfr mutation pl747p in non small cell lung cancer molecular feature and targeting sensitivity to tyrosine kinase inhibitors\n",
      "Drug T0: ['AFATINIB', 'DACOMITINIB', 'OSIMERTINIB']\n",
      "Drug T1: ['ERLOTINIB', 'GEFITINIB', 'OSIMERTINIB', 'AFATINIB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: overcoming osimertinib resistance with akt inhibition in egfrm driven nonsmall cell lung cancer with pik3ca pten alterations\n",
      "Title T1: overcoming osimertinib resistance with akt inhibition in egfrm driven nonsmall cell lung cancer with pik3ca pten alterations\n",
      "Drug T0: ['CAPIVASERTIB', 'OSIMERTINIB']\n",
      "Drug T1: ['OSIMERTINIB', 'CAPIVASERTIB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: evaluation of combined chemotherapy and genomic driven targeted therapy in patient derived xenografts identifies new therapeutic approaches in squamous non small cell lung cancer patients\n",
      "Title T1: evaluation of combined chemotherapy and genomic driven targeted therapy in patient derived xenografts identifies new therapeutic approaches in squamous non small cell lung cancer patients\n",
      "Drug T0: ['AFATINIB', 'TRAMETINIB']\n",
      "Drug T1: ['SORAFENIB', 'GEMCITABINE', 'CISPLATIN', 'BEVACIZUMAB']\n",
      "Overlap: False\n",
      "====================================\n",
      "Title T0: exploration of immune modulatory effects of amivantamab in combination with pembrolizumab in lung and head and neck squamous cell carcinoma\n",
      "Title T1: exploration of immune modulatory effects of amivantamab in combination with pembrolizumab in lung and head and neck squamous cell carcinoma\n",
      "Drug T0: ['PEMBROLIZUMAB', 'AMIVANTAMAB']\n",
      "Drug T1: ['AMIVANTAMAB', 'PEMBROLIZUMAB']\n",
      "Overlap: True\n",
      "====================================\n",
      "Title T0: krt 232 and navitoclax enhance trametinib anti cancer activity in non small cell lung cancer patient derived xenografts with kras mutations\n",
      "Title T1: krt 232 and navitoclax enhance trametinibs anti cancer activity in non small cell lung cancer patient derived xenografts with kras mutations\n",
      "Drug T0: ['NAVTEMADLIN', 'krt232', 'NAVITOCLAX', 'TRAMETINIB']\n",
      "Drug T1: ['TRAMETINIB', 'NAVITOCLAX', 'NAVTEMADLIN']\n",
      "Overlap: True\n",
      "\n",
      "====================================\n",
      "Drug Recall (drug 교집합 1개 이상 기준): 0.8276\n",
      "Matched Titles: 29 / 163\n"
     ]
    }
   ],
   "source": [
    "# ======================================\n",
    "# 1️⃣ Drug 교집합 True/False 확인\n",
    "# ======================================\n",
    "def drug_overlap(row):\n",
    "    # drug_t0와 drug_t1 리스트 간 하나라도 겹치면 True\n",
    "    overlap = any(d in row[\"drug_t1\"] for d in row[\"drug_t0\"])\n",
    "    print(\"====================================\")\n",
    "    print(f\"Title T0: {row['title_t0']}\")\n",
    "    print(f\"Title T1: {row['title_t1']}\")\n",
    "    print(f\"Drug T0: {row['drug_t0']}\")\n",
    "    print(f\"Drug T1: {row['drug_t1']}\")\n",
    "    print(f\"Overlap: {overlap}\")\n",
    "    return overlap\n",
    "\n",
    "matched_df[\"drug_overlap\"] = matched_df.apply(drug_overlap, axis=1)\n",
    "\n",
    "# ======================================\n",
    "# 2️⃣ Drug Recall 계산\n",
    "# ======================================\n",
    "true_positives = matched_df[\"drug_overlap\"].sum()\n",
    "drug_recall = true_positives / len(matched_df) if len(matched_df) > 0 else 0\n",
    "\n",
    "print(\"\\n====================================\")\n",
    "print(f\"Drug Recall (drug 교집합 1개 이상 기준): {drug_recall:.4f}\")\n",
    "print(f\"Matched Titles: {len(matched_df)} / {len(t0)}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "e979142d",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "=== t0 전처리 확인 ===\n",
      "  title                                                                                                                                       \\\n",
      "0  conditionally reprogrammed colorectal cancer cells combined with mouse avatars identify synergy between egfr and mek or cdk4 6 inhibitors   \n",
      "1                combining mek and src inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo   \n",
      "2                                         sensitivity of kras mutant colorectal cancers to combination therapy that cotargets mek and cdk4 6   \n",
      "3                                                              targeting ras mutant colorectal cancer with dual inhibition of mek and cdk4 6   \n",
      "4                                              mcl 1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer   \n",
      "\n",
      "  drug_list                                         \n",
      "0  [cetuximab, palbociclib, sorafenib, trametinib]  \n",
      "1                          [dasatinib, trametinib]  \n",
      "2                        [palbociclib, trametinib]  \n",
      "3                        [palbociclib, trametinib]  \n",
      "4                            [regorafenib, s63845]  \n",
      "=== t1 전처리 확인 ===\n",
      "  title                                                                                                                                          \\\n",
      "0                                                   cdk4 6 inhibitors impede chemoresistance and inhibit tumor growth of small cell lung cancer   \n",
      "1     conditionally reprogrammed colorectal cancer cells combined with mouse avatars identify synergy between egfr and mek or cdk4 6 inhibitors   \n",
      "2  krt 232 and navitoclax enhance trametinibs anti cancer activity in non small cell lung cancer patient derived xenografts with kras mutations   \n",
      "3                           bgb 283 a novel raf kinase and egfr inhibitor displays potent antitumor activity in braf mutated colorectal cancers   \n",
      "4                      acquired resistance to trastuzumab pertuzumab or to t dm1 in vivo can be overcome by her2 kinase inhibition with tas0728   \n",
      "\n",
      "  drug_list                                                              \n",
      "0                                                      [PALLADIUM, LEE]  \n",
      "1                                                                   [-]  \n",
      "2                                 [TRAMETINIB, NAVITOCLAX, NAVTEMADLIN]  \n",
      "3                                  [LIFIRAFENIB, DABRAFENIB, CETUXIMAB]  \n",
      "4  [LAPATINIB, TRASTUZUMAB, PERTUZUMAB, TRASTUZUMAB EMTANSINE, TAS0728]  \n",
      "\n",
      "=== t0 drug_list generic 변환 확인 ===\n",
      "  drug                                            \\\n",
      "0  cetuximab; palbociclib; sorafenib; trametinib   \n",
      "1                          dasatinib; trametinib   \n",
      "2                        palbociclib; trametinib   \n",
      "3                        palbociclib; trametinib   \n",
      "4                            regorafenib; s63845   \n",
      "\n",
      "  drug_list                                         \n",
      "0  [CETUXIMAB, PALBOCICLIB, SORAFENIB, TRAMETINIB]  \n",
      "1                          [DASATINIB, TRAMETINIB]  \n",
      "2                        [PALBOCICLIB, TRAMETINIB]  \n",
      "3                        [PALBOCICLIB, TRAMETINIB]  \n",
      "4                            [REGORAFENIB, s63845]  \n",
      "\n",
      "=== t1 drug_list generic 변환 확인 ===\n",
      "  drug                                                             \\\n",
      "0                                                   PALLADIUM;LEE   \n",
      "1                                                               -   \n",
      "2                               TRAMETINIB;NAVITOCLAX;NAVTEMADLIN   \n",
      "3                                LIFIRAFENIB;DABRAFENIB;CETUXIMAB   \n",
      "4  LAPATINIB;TRASTUZUMAB;PERTUZUMAB;TRASTUZUMAB EMTANSINE;TAS0728   \n",
      "\n",
      "  drug_list                                                              \n",
      "0                                                      [PALLADIUM, LEE]  \n",
      "1                                                                   [-]  \n",
      "2                                 [TRAMETINIB, NAVITOCLAX, NAVTEMADLIN]  \n",
      "3                                  [LIFIRAFENIB, DABRAFENIB, CETUXIMAB]  \n",
      "4  [LAPATINIB, TRASTUZUMAB, PERTUZUMAB, TRASTUZUMAB EMTANSINE, TAS0728]  \n",
      "\n",
      "=== Title 매칭 결과 확인 ===\n",
      "  title_t0                                                                                                                                                                                \\\n",
      "0                                              conditionally reprogrammed colorectal cancer cells combined with mouse avatars identify synergy between egfr and mek or cdk4 6 inhibitors   \n",
      "1                                                                                   activation of the mtor pathway by oxaliplatin in the treatment of colorectal cancer liver metastasis   \n",
      "2                                                                    evaluation of the efficacy of dasatinib a src abl inhibitor in colorectal cancer cell lines and explant mouse model   \n",
      "3                                                                        lowdose trametinib and bclxl antagonist have a specific antitumor effect in krasmutated colorectal cancer cells   \n",
      "4                                                                     bgb 283 a novel raf kinase and egfr inhibitor displays potent antitumor activity inbraf mutated colorectal cancers   \n",
      "5                                                                                                 synergistic anti tumor effect of mtor inhibitors with irinotecan on colon cancer cells   \n",
      "6  integrative in vivo drug testing using gene expression signature and patient derived xenografts from treatment refractory her2 positive and triple negative subtypes of breast cancer   \n",
      "7                                         dual fatty acid synthase and her2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti her2 drugs   \n",
      "8                             dz 2384 has a superior preclinical profile to taxanes for the treatment of triple negative breast cancer and is synergistic with anti ctla 4 immunotherapy   \n",
      "9                                                                                                                 jak2 regulates paclitaxel resistance in triple negative breast cancers   \n",
      "\n",
      "  title_t1                                                                                                                                                                                \\\n",
      "0                                              conditionally reprogrammed colorectal cancer cells combined with mouse avatars identify synergy between egfr and mek or cdk4 6 inhibitors   \n",
      "1                                                                                   activation of the mtor pathway by oxaliplatin in the treatment of colorectal cancer liver metastasis   \n",
      "2                                                                     evaluation of the efficacy of dasatinib a src abl inhibitor in colorectal cancer cell lines and explant mousemodel   \n",
      "3                                                                        lowdose trametinib and bclxl antagonist have a specific antitumor effect in krasmutated colorectal cancer cells   \n",
      "4                                                                    bgb 283 a novel raf kinase and egfr inhibitor displays potent antitumor activity in braf mutated colorectal cancers   \n",
      "5                                                                                                  synergistic anti tumor e ect of mtor inhibitors with irinotecan on colon cancer cells   \n",
      "6  integrative in vivo drug testing using gene expression signature and patient derived xenografts from treatment refractory her2 positive and triple negative subtypes of breast cancer   \n",
      "7                                         dual fatty acid synthase and her2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti her2 drugs   \n",
      "8                             dz 2384 has a superior preclinical profile to taxanes for the treatment of triple negative breast cancer and is synergistic with anti ctla 4 immunotherapy   \n",
      "9                                                                                                                 jak2 regulates paclitaxel resistance in triple negative breast cancers   \n",
      "\n",
      "  drug_t0                                                              \\\n",
      "0                     [CETUXIMAB, PALBOCICLIB, SORAFENIB, TRAMETINIB]   \n",
      "1                                           [EVEROLIMUS, OXALIPLATIN]   \n",
      "2                                                         [DASATINIB]   \n",
      "3                                                [abt263, TRAMETINIB]   \n",
      "4                       [bgb-283 (lifirafenib), CETUXIMAB, ERLOTINIB]   \n",
      "5                              [VISTUSERTIB, IRINOTECAN, OXALIPLATIN]   \n",
      "6  [BEVACIZUMAB, DOCETAXEL, EVEROLIMUS, NERATINIB, PX-478, SORAFENIB]   \n",
      "7                            [EPIGALLOCATECHIN GALLATE, TEMSIROLIMUS]   \n",
      "8                                               [dz-2384, PACLITAXEL]   \n",
      "9                                                        [PACLITAXEL]   \n",
      "\n",
      "  drug_t1                                                                                                                                                           \\\n",
      "0                                                                                                                                                              [-]   \n",
      "1                                                                                                                                        [OXALIPLATIN, EVEROLIMUS]   \n",
      "2                                                                                                                                                      [DASATINIB]   \n",
      "3                                                                                                                                             [TRAMETINIB, ABT263]   \n",
      "4                                                                                                                             [LIFIRAFENIB, DABRAFENIB, CETUXIMAB]   \n",
      "5                                                                                                                                        [IRINOTECAN, VISTUSERTIB]   \n",
      "6                                                                                               [SORAFENIB, EVEROLIMUS, DOCETAXEL, BEVACIZUMAB, PX-478, NERATINIB]   \n",
      "7                                                                                                                             [TRASTUZUMAB, LAPATINIB, PERTUZUMAB]   \n",
      "8  [DOCETAXEL, PACLITAXEL, DZ-2384, METHOTREXATE, CHLORAMBUCIL, anthracyclines, RITONAVIR, ELACRIDAR, SORAFENIB, FULVESTRANT, SUNITINIB, NIVOLUMAB, PEMBROLIZUMAB]   \n",
      "9                                                                                                                                        [PACLITAXEL, GEMCITABINE]   \n",
      "\n",
      "   similarity  \n",
      "0  1.000000    \n",
      "1  1.000000    \n",
      "2  0.855331    \n",
      "3  1.000000    \n",
      "4  0.880090    \n",
      "5  0.846991    \n",
      "6  1.000000    \n",
      "7  1.000000    \n",
      "8  1.000000    \n",
      "9  1.000000    \n",
      "\n",
      "=== Drug Overlap True/False 확인 ===\n",
      "  drug_t0                                                              \\\n",
      "0                     [CETUXIMAB, PALBOCICLIB, SORAFENIB, TRAMETINIB]   \n",
      "1                                           [EVEROLIMUS, OXALIPLATIN]   \n",
      "2                                                         [DASATINIB]   \n",
      "3                                                [abt263, TRAMETINIB]   \n",
      "4                       [bgb-283 (lifirafenib), CETUXIMAB, ERLOTINIB]   \n",
      "5                              [VISTUSERTIB, IRINOTECAN, OXALIPLATIN]   \n",
      "6  [BEVACIZUMAB, DOCETAXEL, EVEROLIMUS, NERATINIB, PX-478, SORAFENIB]   \n",
      "7                            [EPIGALLOCATECHIN GALLATE, TEMSIROLIMUS]   \n",
      "8                                               [dz-2384, PACLITAXEL]   \n",
      "9                                                        [PACLITAXEL]   \n",
      "\n",
      "  drug_t1                                                                                                                                                           \\\n",
      "0                                                                                                                                                              [-]   \n",
      "1                                                                                                                                        [OXALIPLATIN, EVEROLIMUS]   \n",
      "2                                                                                                                                                      [DASATINIB]   \n",
      "3                                                                                                                                             [TRAMETINIB, ABT263]   \n",
      "4                                                                                                                             [LIFIRAFENIB, DABRAFENIB, CETUXIMAB]   \n",
      "5                                                                                                                                        [IRINOTECAN, VISTUSERTIB]   \n",
      "6                                                                                               [SORAFENIB, EVEROLIMUS, DOCETAXEL, BEVACIZUMAB, PX-478, NERATINIB]   \n",
      "7                                                                                                                             [TRASTUZUMAB, LAPATINIB, PERTUZUMAB]   \n",
      "8  [DOCETAXEL, PACLITAXEL, DZ-2384, METHOTREXATE, CHLORAMBUCIL, anthracyclines, RITONAVIR, ELACRIDAR, SORAFENIB, FULVESTRANT, SUNITINIB, NIVOLUMAB, PEMBROLIZUMAB]   \n",
      "9                                                                                                                                        [PACLITAXEL, GEMCITABINE]   \n",
      "\n",
      "   drug_overlap  \n",
      "0  False         \n",
      "1   True         \n",
      "2   True         \n",
      "3   True         \n",
      "4   True         \n",
      "5   True         \n",
      "6   True         \n",
      "7  False         \n",
      "8   True         \n",
      "9   True         \n",
      "\n",
      "Drug Recall (drug 교집합 1개 이상 기준): 0.8276\n",
      "Matched Titles: 29 / 163\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import re\n",
    "from drugname_standardizer import DrugStandardizer\n",
    "from sklearn.feature_extraction.text import TfidfVectorizer\n",
    "from sklearn.metrics.pairwise import cosine_similarity\n",
    "\n",
    "# ======================================\n",
    "# 1️⃣ 전처리 함수\n",
    "# ======================================\n",
    "def preprocess_text(text):\n",
    "    if pd.isna(text):\n",
    "        return \"\"\n",
    "    text = text.lower()\n",
    "    text = re.sub(r\"[^a-z0-9\\s]\", \"\", text)\n",
    "    text = re.sub(r\"\\s+\", \" \", text).strip()\n",
    "    return text\n",
    "\n",
    "def preprocess_drug_list(drug_str):\n",
    "    if pd.isna(drug_str):\n",
    "        return []\n",
    "    return [d.strip() for d in drug_str.split(\";\") if d.strip()]\n",
    "\n",
    "# ======================================\n",
    "# 2️⃣ CSV 불러오기 (예시)\n",
    "# ======================================\n",
    "# t0 = pd.read_csv(\"t0.csv\", encoding=\"utf-8\")\n",
    "# t1 = pd.read_csv(\"t1.csv\", encoding=\"utf-8\")\n",
    "\n",
    "# ======================================\n",
    "# 3️⃣ 컬럼 전처리\n",
    "# ======================================\n",
    "for df_name, df in zip([\"t0\", \"t1\"], [t0, t1]):\n",
    "    df[\"title\"] = df[\"title\"].apply(preprocess_text)\n",
    "    df[\"drug_list\"] = df[\"drug\"].apply(preprocess_drug_list)\n",
    "    print(f\"=== {df_name} 전처리 확인 ===\")\n",
    "    print(df[[\"title\", \"drug_list\"]].head(5))\n",
    "\n",
    "# ======================================\n",
    "# 4️⃣ Drug Generic 변환\n",
    "# ======================================\n",
    "ds = DrugStandardizer()\n",
    "\n",
    "def convert_to_generic(drug_list):\n",
    "    return [ds.standardize_name(d) for d in drug_list]\n",
    "\n",
    "t0[\"drug_list\"] = t0[\"drug_list\"].apply(convert_to_generic)\n",
    "t1[\"drug_list\"] = t1[\"drug_list\"].apply(convert_to_generic)\n",
    "\n",
    "print(\"\\n=== t0 drug_list generic 변환 확인 ===\")\n",
    "print(t0[[\"drug\", \"drug_list\"]].head(5))\n",
    "print(\"\\n=== t1 drug_list generic 변환 확인 ===\")\n",
    "print(t1[[\"drug\", \"drug_list\"]].head(5))\n",
    "\n",
    "# ======================================\n",
    "# 5️⃣ Title 매칭 (cosine similarity)\n",
    "# ======================================\n",
    "def match_titles(t0, t1, threshold=0.8):\n",
    "    vec = TfidfVectorizer().fit(t0[\"title\"].tolist() + t1[\"title\"].tolist())\n",
    "    t0_vec = vec.transform(t0[\"title\"])\n",
    "    t1_vec = vec.transform(t1[\"title\"])\n",
    "    \n",
    "    matches = []\n",
    "    for i, t0_row in t0.iterrows():\n",
    "        sims = cosine_similarity(t0_vec[i], t1_vec).flatten()\n",
    "        max_idx = sims.argmax()\n",
    "        if sims[max_idx] >= threshold:\n",
    "            matches.append({\n",
    "                \"title_t0\": t0_row[\"title\"],\n",
    "                \"title_t1\": t1.iloc[max_idx][\"title\"],\n",
    "                \"drug_t0\": t0_row[\"drug_list\"],\n",
    "                \"drug_t1\": t1.iloc[max_idx][\"drug_list\"],\n",
    "                \"similarity\": sims[max_idx]\n",
    "            })\n",
    "    return pd.DataFrame(matches)\n",
    "\n",
    "matched_df = match_titles(t0, t1, threshold=0.8)\n",
    "print(\"\\n=== Title 매칭 결과 확인 ===\")\n",
    "print(matched_df.head(10))\n",
    "\n",
    "# ======================================\n",
    "# 6️⃣ Drug 교집합 True/False\n",
    "# ======================================\n",
    "def drug_overlap(row):\n",
    "    return any(d in row[\"drug_t1\"] for d in row[\"drug_t0\"])\n",
    "\n",
    "matched_df[\"drug_overlap\"] = matched_df.apply(drug_overlap, axis=1)\n",
    "print(\"\\n=== Drug Overlap True/False 확인 ===\")\n",
    "print(matched_df[[\"drug_t0\", \"drug_t1\", \"drug_overlap\"]].head(10))\n",
    "\n",
    "# ======================================\n",
    "# 7️⃣ Drug Recall 계산\n",
    "# ======================================\n",
    "true_positives = matched_df[\"drug_overlap\"].sum()\n",
    "drug_recall = true_positives / len(matched_df) if len(matched_df) > 0 else 0\n",
    "print(f\"\\nDrug Recall (drug 교집합 1개 이상 기준): {drug_recall:.4f}\")\n",
    "print(f\"Matched Titles: {len(matched_df)} / {len(t0)}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "8e4450fd",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "====================================\n",
      "🔹 행별 평균 재현율 (mean of per-row recall): 0.6293\n",
      "🔹 True 비율 기반 재현율 (overall recall): 0.8276\n",
      "====================================\n",
      "Index: 0\n",
      "Title T0: conditionally reprogrammed colorectal cancer cells combined with mouse avatars i...\n",
      "Recall (row): 0.0\n",
      "Drug T0: ['CETUXIMAB', 'PALBOCICLIB', 'SORAFENIB', 'TRAMETINIB']\n",
      "Drug T1: ['-']\n",
      "------------------------------------\n",
      "Index: 1\n",
      "Title T0: activation of the mtor pathway by oxaliplatin in the treatment of colorectal can...\n",
      "Recall (row): 1.0\n",
      "Drug T0: ['EVEROLIMUS', 'OXALIPLATIN']\n",
      "Drug T1: ['OXALIPLATIN', 'EVEROLIMUS']\n",
      "------------------------------------\n",
      "Index: 2\n",
      "Title T0: evaluation of the efficacy of dasatinib a src abl inhibitor in colorectal cancer...\n",
      "Recall (row): 1.0\n",
      "Drug T0: ['DASATINIB']\n",
      "Drug T1: ['DASATINIB']\n",
      "------------------------------------\n",
      "Index: 3\n",
      "Title T0: lowdose trametinib and bclxl antagonist have a specific antitumor effect in kras...\n",
      "Recall (row): 0.5\n",
      "Drug T0: ['abt263', 'TRAMETINIB']\n",
      "Drug T1: ['TRAMETINIB', 'ABT263']\n",
      "------------------------------------\n",
      "Index: 4\n",
      "Title T0: bgb 283 a novel raf kinase and egfr inhibitor displays potent antitumor activity...\n",
      "Recall (row): 0.3333333333333333\n",
      "Drug T0: ['bgb-283 (lifirafenib)', 'CETUXIMAB', 'ERLOTINIB']\n",
      "Drug T1: ['LIFIRAFENIB', 'DABRAFENIB', 'CETUXIMAB']\n",
      "------------------------------------\n",
      "Index: 5\n",
      "Title T0: synergistic anti tumor effect of mtor inhibitors with irinotecan on colon cancer...\n",
      "Recall (row): 0.6666666666666666\n",
      "Drug T0: ['VISTUSERTIB', 'IRINOTECAN', 'OXALIPLATIN']\n",
      "Drug T1: ['IRINOTECAN', 'VISTUSERTIB']\n",
      "------------------------------------\n",
      "Index: 6\n",
      "Title T0: integrative in vivo drug testing using gene expression signature and patient der...\n",
      "Recall (row): 1.0\n",
      "Drug T0: ['BEVACIZUMAB', 'DOCETAXEL', 'EVEROLIMUS', 'NERATINIB', 'PX-478', 'SORAFENIB']\n",
      "Drug T1: ['SORAFENIB', 'EVEROLIMUS', 'DOCETAXEL', 'BEVACIZUMAB', 'PX-478', 'NERATINIB']\n",
      "------------------------------------\n",
      "Index: 7\n",
      "Title T0: dual fatty acid synthase and her2 signaling blockade shows marked antitumor acti...\n",
      "Recall (row): 0.0\n",
      "Drug T0: ['EPIGALLOCATECHIN GALLATE', 'TEMSIROLIMUS']\n",
      "Drug T1: ['TRASTUZUMAB', 'LAPATINIB', 'PERTUZUMAB']\n",
      "------------------------------------\n",
      "Index: 8\n",
      "Title T0: dz 2384 has a superior preclinical profile to taxanes for the treatment of tripl...\n",
      "Recall (row): 0.5\n",
      "Drug T0: ['dz-2384', 'PACLITAXEL']\n",
      "Drug T1: ['DOCETAXEL', 'PACLITAXEL', 'DZ-2384', 'METHOTREXATE', 'CHLORAMBUCIL', 'anthracyclines', 'RITONAVIR', 'ELACRIDAR', 'SORAFENIB', 'FULVESTRANT', 'SUNITINIB', 'NIVOLUMAB', 'PEMBROLIZUMAB']\n",
      "------------------------------------\n",
      "Index: 9\n",
      "Title T0: jak2 regulates paclitaxel resistance in triple negative breast cancers...\n",
      "Recall (row): 1.0\n",
      "Drug T0: ['PACLITAXEL']\n",
      "Drug T1: ['PACLITAXEL', 'GEMCITABINE']\n",
      "------------------------------------\n",
      "Index: 10\n",
      "Title T0: wnt catenin inhibition disrupts carboplatin resistance in isogenic models of tri...\n",
      "Recall (row): 0.5\n",
      "Drug T0: ['CARBOPLATIN', 'WNT-974']\n",
      "Drug T1: ['CARBOPLATIN', 'Wnt inhibitor', 'CHIR', 'DIMETHYL SULFOXIDE']\n",
      "------------------------------------\n",
      "Index: 11\n",
      "Title T0: acquired resistance to trastuzumab pertuzumab or to t dm1 in vivo can be overcom...\n",
      "Recall (row): 0.6666666666666666\n",
      "Drug T0: ['tas0728', 'TRASTUZUMAB', 'PERTUZUMAB']\n",
      "Drug T1: ['LAPATINIB', 'TRASTUZUMAB', 'PERTUZUMAB', 'TRASTUZUMAB EMTANSINE', 'TAS0728']\n",
      "------------------------------------\n",
      "Index: 12\n",
      "Title T0: the iron chelator deferasirox synergises with chemotherapy to treat triple negat...\n",
      "Recall (row): 0.3333333333333333\n",
      "Drug T0: ['adriamycin (doxorubicin)', 'dfx', 'CYCLOPHOSPHAMIDE']\n",
      "Drug T1: ['DOXORUBICIN', 'CISPLATIN', 'CARBOPLATIN', 'CYCLOPHOSPHAMIDE', 'DEFERASIROX']\n",
      "------------------------------------\n",
      "Index: 13\n",
      "Title T0: identification of src family kinases as potential therapeutic targets for chemot...\n",
      "Recall (row): 1.0\n",
      "Drug T0: ['DASATINIB', 'PACLITAXEL']\n",
      "Drug T1: ['DASATINIB', 'PACLITAXEL']\n",
      "------------------------------------\n",
      "Index: 14\n",
      "Title T0: evaluation of combined chemotherapy and genomic driven targeted therapy in patie...\n",
      "Recall (row): 0.3333333333333333\n",
      "Drug T0: ['CARBOPLATIN', 'CISPLATIN', 'ETOPOSIDE', 'GEMCITABINE', 'PACLITAXEL', 'PEMETREXED']\n",
      "Drug T1: ['SORAFENIB', 'GEMCITABINE', 'CISPLATIN', 'BEVACIZUMAB']\n",
      "------------------------------------\n",
      "Index: 15\n",
      "Title T0: cdk4 6 inhibitors impede chemoresistance and inhibit tumor growth of small cell ...\n",
      "Recall (row): 0.0\n",
      "Drug T0: ['CISPLATIN', 'ETOPOSIDE']\n",
      "Drug T1: ['PALLADIUM', 'LEE']\n",
      "------------------------------------\n",
      "Index: 16\n",
      "Title T0: cisplatin increases sensitivity to fgfr inhibition in patient derived xenograft ...\n",
      "Recall (row): 1.0\n",
      "Drug T0: ['INFIGRATINIB', 'CISPLATIN']\n",
      "Drug T1: ['CISPLATIN', 'INFIGRATINIB']\n",
      "------------------------------------\n",
      "Index: 17\n",
      "Title T0: sensitization of egfr wild type nonsmall cell lung cancer cells to egfr tyrosine...\n",
      "Recall (row): 1.0\n",
      "Drug T0: ['CISPLATIN', 'ERLOTINIB']\n",
      "Drug T1: ['CISPLATIN', 'ERLOTINIB']\n",
      "------------------------------------\n",
      "Index: 18\n",
      "Title T0: oral estrogen receptor protac vepdegestrant arv 471 is highly efficacious as mon...\n",
      "Recall (row): 1.0\n",
      "Drug T0: ['FULVESTRANT']\n",
      "Drug T1: ['FULVESTRANT', 'AZD-9496', 'VEPDEGESTRANT']\n",
      "------------------------------------\n",
      "Index: 19\n",
      "Title T0: her4 affects sensitivity to tamoxifen and abemaciclib in luminal breast cancer c...\n",
      "Recall (row): 0.0\n",
      "Drug T0: ['ABEMACICLIB', 'TAMOXIFEN']\n",
      "Drug T1: ['RITUXIMAB', 'PEMBROLIZUMAB', 'NIVOLUMAB', 'FULVESTRANT', 'SUNITINIB']\n",
      "------------------------------------\n",
      "Index: 20\n",
      "Title T0: mediator kinase inhibitors suppress triple negative breast cancer growth and ext...\n",
      "Recall (row): 0.5\n",
      "Drug T0: ['CAPIVASERTIB', 'EVEROLIMUS']\n",
      "Drug T1: ['EVEROLIMUS', 'CDK8/19i']\n",
      "------------------------------------\n",
      "Index: 21\n",
      "Title T0: brca1 methylated triple negative breast cancers previously exposed to neoadjuvan...\n",
      "Recall (row): 0.5\n",
      "Drug T0: ['CARBOPLATIN', 'OLAPARIB']\n",
      "Drug T1: ['OLAPARIB', '4-CHLOROBENZOPHENONE']\n",
      "------------------------------------\n",
      "Index: 22\n",
      "Title T0: rb expression confers sensitivity to cdk4 6 inhibitormediated radiosensitization...\n",
      "Recall (row): 1.0\n",
      "Drug T0: ['ABEMACICLIB', 'PALBOCICLIB']\n",
      "Drug T1: ['PALBOCICLIB', 'RIBOCICLIB', 'ABEMACICLIB']\n",
      "------------------------------------\n",
      "Index: 23\n",
      "Title T0: comparative study on the efficacy and exposure of molecular target agents in non...\n",
      "Recall (row): 1.0\n",
      "Drug T0: ['AFATINIB', 'BRIGATINIB', 'CRIZOTINIB', 'ENTRECTINIB', 'GEFITINIB', 'LORLATINIB', 'OSIMERTINIB']\n",
      "Drug T1: ['GEFITINIB', 'OSIMERTINIB', 'AFATINIB', 'CRIZOTINIB', 'ENTRECTINIB', 'BRIGATINIB', 'LORLATINIB', 'POZIOTINIB', 'TRASTUZUMAB DERUXTECAN']\n",
      "------------------------------------\n",
      "Index: 24\n",
      "Title T0: the lifted veil of uncommon egfr mutation pl747p in non small cell lung cancer m...\n",
      "Recall (row): 0.6666666666666666\n",
      "Drug T0: ['AFATINIB', 'DACOMITINIB', 'OSIMERTINIB']\n",
      "Drug T1: ['ERLOTINIB', 'GEFITINIB', 'OSIMERTINIB', 'AFATINIB']\n",
      "------------------------------------\n",
      "Index: 25\n",
      "Title T0: overcoming osimertinib resistance with akt inhibition in egfrm driven nonsmall c...\n",
      "Recall (row): 1.0\n",
      "Drug T0: ['CAPIVASERTIB', 'OSIMERTINIB']\n",
      "Drug T1: ['OSIMERTINIB', 'CAPIVASERTIB']\n",
      "------------------------------------\n",
      "Index: 26\n",
      "Title T0: evaluation of combined chemotherapy and genomic driven targeted therapy in patie...\n",
      "Recall (row): 0.0\n",
      "Drug T0: ['AFATINIB', 'TRAMETINIB']\n",
      "Drug T1: ['SORAFENIB', 'GEMCITABINE', 'CISPLATIN', 'BEVACIZUMAB']\n",
      "------------------------------------\n",
      "Index: 27\n",
      "Title T0: exploration of immune modulatory effects of amivantamab in combination with pemb...\n",
      "Recall (row): 1.0\n",
      "Drug T0: ['PEMBROLIZUMAB', 'AMIVANTAMAB']\n",
      "Drug T1: ['AMIVANTAMAB', 'PEMBROLIZUMAB']\n",
      "------------------------------------\n",
      "Index: 28\n",
      "Title T0: krt 232 and navitoclax enhance trametinib anti cancer activity in non small cell...\n",
      "Recall (row): 0.75\n",
      "Drug T0: ['NAVTEMADLIN', 'krt232', 'NAVITOCLAX', 'TRAMETINIB']\n",
      "Drug T1: ['TRAMETINIB', 'NAVITOCLAX', 'NAVTEMADLIN']\n",
      "------------------------------------\n"
     ]
    }
   ],
   "source": [
    "# ======================================\n",
    "# 6️⃣ Drug Recall (개별 행별 recall 포함)\n",
    "# ======================================\n",
    "def compute_row_recall(row):\n",
    "    set_true = set(row[\"drug_t0\"])\n",
    "    set_pred = set(row[\"drug_t1\"])\n",
    "    if len(set_true) == 0:\n",
    "        return None  # 정답이 없는 경우 제외\n",
    "    inter = len(set_true & set_pred)\n",
    "    recall = inter / len(set_true)\n",
    "    return recall\n",
    "\n",
    "# 각 행별 recall 계산\n",
    "matched_df[\"row_recall\"] = matched_df.apply(compute_row_recall, axis=1)\n",
    "\n",
    "# 전체 평균 (nan 제외)\n",
    "mean_row_recall = matched_df[\"row_recall\"].dropna().mean()\n",
    "\n",
    "# 기존 방식: True 비율 기반 recall\n",
    "true_positives = matched_df[\"drug_overlap\"].sum()\n",
    "overall_recall = true_positives / len(matched_df) if len(matched_df) > 0 else 0\n",
    "\n",
    "# 결과 출력\n",
    "print(\"\\n====================================\")\n",
    "print(f\"🔹 행별 평균 재현율 (mean of per-row recall): {mean_row_recall:.4f}\")\n",
    "print(f\"🔹 True 비율 기반 재현율 (overall recall): {overall_recall:.4f}\")\n",
    "print(\"====================================\")\n",
    "\n",
    "# 행별 상세 출력\n",
    "for idx, row in matched_df.iterrows():\n",
    "    print(f\"Index: {idx}\")\n",
    "    print(f\"Title T0: {row['title_t0'][:80]}...\")\n",
    "    print(f\"Recall (row): {row['row_recall']}\")\n",
    "    print(f\"Drug T0: {row['drug_t0']}\")\n",
    "    print(f\"Drug T1: {row['drug_t1']}\")\n",
    "    print(\"------------------------------------\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "5e3291cc",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "====================================\n",
      "🔹 행별 평균 지표 (매크로 평균)\n",
      "Macro Precision : 0.5530\n",
      "Macro Recall    : 0.6293\n",
      "Macro F1         : 0.6883\n",
      "------------------------------------\n",
      "🔸 전체 통합 지표 (마이크로 평균)\n",
      "Micro Precision : 0.4800\n",
      "Micro Recall    : 0.6234\n",
      "Micro F1         : 0.5424\n",
      "====================================\n",
      "Index: 0\n",
      "Title T0: conditionally reprogrammed colorectal cancer cells combined with mouse avatars i...\n",
      "Precision: 0.0, Recall: 0.0, F1: nan\n",
      "Drug T0: ['CETUXIMAB', 'PALBOCICLIB', 'SORAFENIB', 'TRAMETINIB']\n",
      "Drug T1: ['-']\n",
      "------------------------------------\n",
      "Index: 1\n",
      "Title T0: activation of the mtor pathway by oxaliplatin in the treatment of colorectal can...\n",
      "Precision: 1.0, Recall: 1.0, F1: 1.0\n",
      "Drug T0: ['EVEROLIMUS', 'OXALIPLATIN']\n",
      "Drug T1: ['OXALIPLATIN', 'EVEROLIMUS']\n",
      "------------------------------------\n",
      "Index: 2\n",
      "Title T0: evaluation of the efficacy of dasatinib a src abl inhibitor in colorectal cancer...\n",
      "Precision: 1.0, Recall: 1.0, F1: 1.0\n",
      "Drug T0: ['DASATINIB']\n",
      "Drug T1: ['DASATINIB']\n",
      "------------------------------------\n",
      "Index: 3\n",
      "Title T0: lowdose trametinib and bclxl antagonist have a specific antitumor effect in kras...\n",
      "Precision: 0.5, Recall: 0.5, F1: 0.5\n",
      "Drug T0: ['abt263', 'TRAMETINIB']\n",
      "Drug T1: ['TRAMETINIB', 'ABT263']\n",
      "------------------------------------\n",
      "Index: 4\n",
      "Title T0: bgb 283 a novel raf kinase and egfr inhibitor displays potent antitumor activity...\n",
      "Precision: 0.3333333333333333, Recall: 0.3333333333333333, F1: 0.3333333333333333\n",
      "Drug T0: ['bgb-283 (lifirafenib)', 'CETUXIMAB', 'ERLOTINIB']\n",
      "Drug T1: ['LIFIRAFENIB', 'DABRAFENIB', 'CETUXIMAB']\n",
      "------------------------------------\n",
      "Index: 5\n",
      "Title T0: synergistic anti tumor effect of mtor inhibitors with irinotecan on colon cancer...\n",
      "Precision: 1.0, Recall: 0.6666666666666666, F1: 0.8\n",
      "Drug T0: ['VISTUSERTIB', 'IRINOTECAN', 'OXALIPLATIN']\n",
      "Drug T1: ['IRINOTECAN', 'VISTUSERTIB']\n",
      "------------------------------------\n",
      "Index: 6\n",
      "Title T0: integrative in vivo drug testing using gene expression signature and patient der...\n",
      "Precision: 1.0, Recall: 1.0, F1: 1.0\n",
      "Drug T0: ['BEVACIZUMAB', 'DOCETAXEL', 'EVEROLIMUS', 'NERATINIB', 'PX-478', 'SORAFENIB']\n",
      "Drug T1: ['SORAFENIB', 'EVEROLIMUS', 'DOCETAXEL', 'BEVACIZUMAB', 'PX-478', 'NERATINIB']\n",
      "------------------------------------\n",
      "Index: 7\n",
      "Title T0: dual fatty acid synthase and her2 signaling blockade shows marked antitumor acti...\n",
      "Precision: 0.0, Recall: 0.0, F1: nan\n",
      "Drug T0: ['EPIGALLOCATECHIN GALLATE', 'TEMSIROLIMUS']\n",
      "Drug T1: ['TRASTUZUMAB', 'LAPATINIB', 'PERTUZUMAB']\n",
      "------------------------------------\n",
      "Index: 8\n",
      "Title T0: dz 2384 has a superior preclinical profile to taxanes for the treatment of tripl...\n",
      "Precision: 0.07692307692307693, Recall: 0.5, F1: 0.13333333333333336\n",
      "Drug T0: ['dz-2384', 'PACLITAXEL']\n",
      "Drug T1: ['DOCETAXEL', 'PACLITAXEL', 'DZ-2384', 'METHOTREXATE', 'CHLORAMBUCIL', 'anthracyclines', 'RITONAVIR', 'ELACRIDAR', 'SORAFENIB', 'FULVESTRANT', 'SUNITINIB', 'NIVOLUMAB', 'PEMBROLIZUMAB']\n",
      "------------------------------------\n",
      "Index: 9\n",
      "Title T0: jak2 regulates paclitaxel resistance in triple negative breast cancers...\n",
      "Precision: 0.5, Recall: 1.0, F1: 0.6666666666666666\n",
      "Drug T0: ['PACLITAXEL']\n",
      "Drug T1: ['PACLITAXEL', 'GEMCITABINE']\n",
      "------------------------------------\n",
      "Index: 10\n",
      "Title T0: wnt catenin inhibition disrupts carboplatin resistance in isogenic models of tri...\n",
      "Precision: 0.25, Recall: 0.5, F1: 0.3333333333333333\n",
      "Drug T0: ['CARBOPLATIN', 'WNT-974']\n",
      "Drug T1: ['CARBOPLATIN', 'Wnt inhibitor', 'CHIR', 'DIMETHYL SULFOXIDE']\n",
      "------------------------------------\n",
      "Index: 11\n",
      "Title T0: acquired resistance to trastuzumab pertuzumab or to t dm1 in vivo can be overcom...\n",
      "Precision: 0.4, Recall: 0.6666666666666666, F1: 0.5\n",
      "Drug T0: ['tas0728', 'TRASTUZUMAB', 'PERTUZUMAB']\n",
      "Drug T1: ['LAPATINIB', 'TRASTUZUMAB', 'PERTUZUMAB', 'TRASTUZUMAB EMTANSINE', 'TAS0728']\n",
      "------------------------------------\n",
      "Index: 12\n",
      "Title T0: the iron chelator deferasirox synergises with chemotherapy to treat triple negat...\n",
      "Precision: 0.2, Recall: 0.3333333333333333, F1: 0.25\n",
      "Drug T0: ['adriamycin (doxorubicin)', 'dfx', 'CYCLOPHOSPHAMIDE']\n",
      "Drug T1: ['DOXORUBICIN', 'CISPLATIN', 'CARBOPLATIN', 'CYCLOPHOSPHAMIDE', 'DEFERASIROX']\n",
      "------------------------------------\n",
      "Index: 13\n",
      "Title T0: identification of src family kinases as potential therapeutic targets for chemot...\n",
      "Precision: 1.0, Recall: 1.0, F1: 1.0\n",
      "Drug T0: ['DASATINIB', 'PACLITAXEL']\n",
      "Drug T1: ['DASATINIB', 'PACLITAXEL']\n",
      "------------------------------------\n",
      "Index: 14\n",
      "Title T0: evaluation of combined chemotherapy and genomic driven targeted therapy in patie...\n",
      "Precision: 0.5, Recall: 0.3333333333333333, F1: 0.4\n",
      "Drug T0: ['CARBOPLATIN', 'CISPLATIN', 'ETOPOSIDE', 'GEMCITABINE', 'PACLITAXEL', 'PEMETREXED']\n",
      "Drug T1: ['SORAFENIB', 'GEMCITABINE', 'CISPLATIN', 'BEVACIZUMAB']\n",
      "------------------------------------\n",
      "Index: 15\n",
      "Title T0: cdk4 6 inhibitors impede chemoresistance and inhibit tumor growth of small cell ...\n",
      "Precision: 0.0, Recall: 0.0, F1: nan\n",
      "Drug T0: ['CISPLATIN', 'ETOPOSIDE']\n",
      "Drug T1: ['PALLADIUM', 'LEE']\n",
      "------------------------------------\n",
      "Index: 16\n",
      "Title T0: cisplatin increases sensitivity to fgfr inhibition in patient derived xenograft ...\n",
      "Precision: 1.0, Recall: 1.0, F1: 1.0\n",
      "Drug T0: ['INFIGRATINIB', 'CISPLATIN']\n",
      "Drug T1: ['CISPLATIN', 'INFIGRATINIB']\n",
      "------------------------------------\n",
      "Index: 17\n",
      "Title T0: sensitization of egfr wild type nonsmall cell lung cancer cells to egfr tyrosine...\n",
      "Precision: 1.0, Recall: 1.0, F1: 1.0\n",
      "Drug T0: ['CISPLATIN', 'ERLOTINIB']\n",
      "Drug T1: ['CISPLATIN', 'ERLOTINIB']\n",
      "------------------------------------\n",
      "Index: 18\n",
      "Title T0: oral estrogen receptor protac vepdegestrant arv 471 is highly efficacious as mon...\n",
      "Precision: 0.3333333333333333, Recall: 1.0, F1: 0.5\n",
      "Drug T0: ['FULVESTRANT']\n",
      "Drug T1: ['FULVESTRANT', 'AZD-9496', 'VEPDEGESTRANT']\n",
      "------------------------------------\n",
      "Index: 19\n",
      "Title T0: her4 affects sensitivity to tamoxifen and abemaciclib in luminal breast cancer c...\n",
      "Precision: 0.0, Recall: 0.0, F1: nan\n",
      "Drug T0: ['ABEMACICLIB', 'TAMOXIFEN']\n",
      "Drug T1: ['RITUXIMAB', 'PEMBROLIZUMAB', 'NIVOLUMAB', 'FULVESTRANT', 'SUNITINIB']\n",
      "------------------------------------\n",
      "Index: 20\n",
      "Title T0: mediator kinase inhibitors suppress triple negative breast cancer growth and ext...\n",
      "Precision: 0.5, Recall: 0.5, F1: 0.5\n",
      "Drug T0: ['CAPIVASERTIB', 'EVEROLIMUS']\n",
      "Drug T1: ['EVEROLIMUS', 'CDK8/19i']\n",
      "------------------------------------\n",
      "Index: 21\n",
      "Title T0: brca1 methylated triple negative breast cancers previously exposed to neoadjuvan...\n",
      "Precision: 0.5, Recall: 0.5, F1: 0.5\n",
      "Drug T0: ['CARBOPLATIN', 'OLAPARIB']\n",
      "Drug T1: ['OLAPARIB', '4-CHLOROBENZOPHENONE']\n",
      "------------------------------------\n",
      "Index: 22\n",
      "Title T0: rb expression confers sensitivity to cdk4 6 inhibitormediated radiosensitization...\n",
      "Precision: 0.6666666666666666, Recall: 1.0, F1: 0.8\n",
      "Drug T0: ['ABEMACICLIB', 'PALBOCICLIB']\n",
      "Drug T1: ['PALBOCICLIB', 'RIBOCICLIB', 'ABEMACICLIB']\n",
      "------------------------------------\n",
      "Index: 23\n",
      "Title T0: comparative study on the efficacy and exposure of molecular target agents in non...\n",
      "Precision: 0.7777777777777778, Recall: 1.0, F1: 0.8750000000000001\n",
      "Drug T0: ['AFATINIB', 'BRIGATINIB', 'CRIZOTINIB', 'ENTRECTINIB', 'GEFITINIB', 'LORLATINIB', 'OSIMERTINIB']\n",
      "Drug T1: ['GEFITINIB', 'OSIMERTINIB', 'AFATINIB', 'CRIZOTINIB', 'ENTRECTINIB', 'BRIGATINIB', 'LORLATINIB', 'POZIOTINIB', 'TRASTUZUMAB DERUXTECAN']\n",
      "------------------------------------\n",
      "Index: 24\n",
      "Title T0: the lifted veil of uncommon egfr mutation pl747p in non small cell lung cancer m...\n",
      "Precision: 0.5, Recall: 0.6666666666666666, F1: 0.5714285714285715\n",
      "Drug T0: ['AFATINIB', 'DACOMITINIB', 'OSIMERTINIB']\n",
      "Drug T1: ['ERLOTINIB', 'GEFITINIB', 'OSIMERTINIB', 'AFATINIB']\n",
      "------------------------------------\n",
      "Index: 25\n",
      "Title T0: overcoming osimertinib resistance with akt inhibition in egfrm driven nonsmall c...\n",
      "Precision: 1.0, Recall: 1.0, F1: 1.0\n",
      "Drug T0: ['CAPIVASERTIB', 'OSIMERTINIB']\n",
      "Drug T1: ['OSIMERTINIB', 'CAPIVASERTIB']\n",
      "------------------------------------\n",
      "Index: 26\n",
      "Title T0: evaluation of combined chemotherapy and genomic driven targeted therapy in patie...\n",
      "Precision: 0.0, Recall: 0.0, F1: nan\n",
      "Drug T0: ['AFATINIB', 'TRAMETINIB']\n",
      "Drug T1: ['SORAFENIB', 'GEMCITABINE', 'CISPLATIN', 'BEVACIZUMAB']\n",
      "------------------------------------\n",
      "Index: 27\n",
      "Title T0: exploration of immune modulatory effects of amivantamab in combination with pemb...\n",
      "Precision: 1.0, Recall: 1.0, F1: 1.0\n",
      "Drug T0: ['PEMBROLIZUMAB', 'AMIVANTAMAB']\n",
      "Drug T1: ['AMIVANTAMAB', 'PEMBROLIZUMAB']\n",
      "------------------------------------\n",
      "Index: 28\n",
      "Title T0: krt 232 and navitoclax enhance trametinib anti cancer activity in non small cell...\n",
      "Precision: 1.0, Recall: 0.75, F1: 0.8571428571428571\n",
      "Drug T0: ['NAVTEMADLIN', 'krt232', 'NAVITOCLAX', 'TRAMETINIB']\n",
      "Drug T1: ['TRAMETINIB', 'NAVITOCLAX', 'NAVTEMADLIN']\n",
      "------------------------------------\n"
     ]
    }
   ],
   "source": [
    "# ======================================\n",
    "# 6️⃣ Drug Recall (개별 행별 recall 포함)\n",
    "# ======================================\n",
    "def compute_row_recall(row):\n",
    "    set_true = set(row[\"drug_t0\"])\n",
    "    set_pred = set(row[\"drug_t1\"])\n",
    "    if len(set_true) == 0:\n",
    "        return None  # 정답이 없는 경우 제외\n",
    "    inter = len(set_true & set_pred)\n",
    "    recall = inter / len(set_true)\n",
    "    return recall\n",
    "\n",
    "def compute_row_precision(row):\n",
    "    set_true = set(row[\"drug_t0\"])\n",
    "    set_pred = set(row[\"drug_t1\"])\n",
    "    if len(set_pred) == 0:\n",
    "        return None  # 예측이 없는 경우 제외\n",
    "    inter = len(set_true & set_pred)\n",
    "    precision = inter / len(set_pred)\n",
    "    return precision\n",
    "\n",
    "# 행별 recall, precision, f1 계산\n",
    "matched_df[\"row_recall\"] = matched_df.apply(compute_row_recall, axis=1)\n",
    "matched_df[\"row_precision\"] = matched_df.apply(compute_row_precision, axis=1)\n",
    "\n",
    "def compute_row_f1(row):\n",
    "    p, r = row[\"row_precision\"], row[\"row_recall\"]\n",
    "    if pd.isna(p) or pd.isna(r) or (p + r == 0):\n",
    "        return None\n",
    "    return 2 * p * r / (p + r)\n",
    "\n",
    "matched_df[\"row_f1\"] = matched_df.apply(compute_row_f1, axis=1)\n",
    "\n",
    "# 전체 평균 (매크로)\n",
    "macro_recall = matched_df[\"row_recall\"].dropna().mean()\n",
    "macro_precision = matched_df[\"row_precision\"].dropna().mean()\n",
    "macro_f1 = matched_df[\"row_f1\"].dropna().mean()\n",
    "\n",
    "# 마이크로 평균 계산 (전체 TP/FP/FN 합산 기준)\n",
    "tp, fp, fn = 0, 0, 0\n",
    "for _, row in matched_df.iterrows():\n",
    "    set_true = set(row[\"drug_t0\"])\n",
    "    set_pred = set(row[\"drug_t1\"])\n",
    "    tp += len(set_true & set_pred)\n",
    "    fp += len(set_pred - set_true)\n",
    "    fn += len(set_true - set_pred)\n",
    "\n",
    "micro_precision = tp / (tp + fp) if (tp + fp) > 0 else 0\n",
    "micro_recall = tp / (tp + fn) if (tp + fn) > 0 else 0\n",
    "micro_f1 = 2 * micro_precision * micro_recall / (micro_precision + micro_recall) if (micro_precision + micro_recall) > 0 else 0\n",
    "\n",
    "# 결과 출력\n",
    "print(\"\\n====================================\")\n",
    "print(\"🔹 행별 평균 지표 (매크로 평균)\")\n",
    "print(f\"Macro Precision : {macro_precision:.4f}\")\n",
    "print(f\"Macro Recall    : {macro_recall:.4f}\")\n",
    "print(f\"Macro F1         : {macro_f1:.4f}\")\n",
    "print(\"------------------------------------\")\n",
    "print(\"🔸 전체 통합 지표 (마이크로 평균)\")\n",
    "print(f\"Micro Precision : {micro_precision:.4f}\")\n",
    "print(f\"Micro Recall    : {micro_recall:.4f}\")\n",
    "print(f\"Micro F1         : {micro_f1:.4f}\")\n",
    "print(\"====================================\")\n",
    "\n",
    "# 행별 상세 출력 (원하면 주석 처리 가능)\n",
    "for idx, row in matched_df.iterrows():\n",
    "    print(f\"Index: {idx}\")\n",
    "    print(f\"Title T0: {row['title_t0'][:80]}...\")\n",
    "    print(f\"Precision: {row['row_precision']}, Recall: {row['row_recall']}, F1: {row['row_f1']}\")\n",
    "    print(f\"Drug T0: {row['drug_t0']}\")\n",
    "    print(f\"Drug T1: {row['drug_t1']}\")\n",
    "    print(\"------------------------------------\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "id": "006e61bf",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "✅ 매칭 및 재현율 결과가 'matched_result.csv'에 저장되었습니다.\n"
     ]
    }
   ],
   "source": [
    "# ======================================\n",
    "# ✅ 매칭 및 재현율 결과 저장 코드\n",
    "# ======================================\n",
    "\n",
    "# 1️⃣ 행별 매칭 결과 저장\n",
    "output_path = \"matched_result.csv\"\n",
    "matched_df.to_csv(output_path, index=False, encoding=\"utf-8-sig\")\n",
    "\n",
    "# 2️⃣ 전체 통계 요약 딕셔너리 생성\n",
    "summary_data = {\n",
    "    \"mean_row_recall\": [mean_row_recall],\n",
    "    \"overall_recall\": [overall_recall],\n",
    "    \"macro_recall\": [macro_recall],\n",
    "    \"micro_recall\": [micro_recall],\n",
    "    \"f1_score\": [f1_score]\n",
    "}\n",
    "\n",
    "# 3️⃣ 요약정보를 새로운 시트(또는 아래줄)에 추가 저장\n",
    "summary_df = pd.DataFrame(summary_data)\n",
    "\n",
    "# 4️⃣ 기존 파일에 이어붙이기\n",
    "with open(output_path, \"a\", encoding=\"utf-8-sig\") as f:\n",
    "    f.write(\"\\n\\n=== Summary Statistics ===\\n\")\n",
    "summary_df.to_csv(output_path, mode=\"a\", index=False, encoding=\"utf-8-sig\")\n",
    "\n",
    "print(f\"✅ 매칭 및 재현율 결과가 '{output_path}'에 저장되었습니다.\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "46a6f4df",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python (rag_env)",
   "language": "python",
   "name": "rag_env"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.18"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
